JAB-2485
JAB-2485 is an orally active and selective Aurora kinase A (AURKA) inhibitor with an IC50 value of 0.327 nM. JAB-2485 exhibits inhibitory activity against various tumor cell lines such as neuroblastoma, triple-negative breast cancer, small cell lung cancer, and epithelial ovarian cancer. JAB-2485 can induce cell cycle arrest and apoptosis in tumor cells. JAB-2485 has antitumor activity[1][2].
Product Specifications
CAS Number
2899209-55-1
UNSPSC
12352005
Target
Apoptosis; Aurora Kinase; Caspase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jab-2485.html
Purity
98.11
Solubility
DMSO : ≥ 100 mg/mL
Smiles
ClC1=CC=CC(CN2CC[C@](C(O)=O)(CC3=CC(C)=C(F)C(NC4=CC(C)=NN4)=N3)C[C@H]2C)=C1F
Molecular Formula
C25H28ClF2N5O2
Molecular Weight
503.97
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Aurora A; Caspase 3; Caspase 7
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Nucleolin (NCL/902), Biotin conjugate, 0.1mg/mL
HPV16 E1/E4 (Human Papilloma Virus 16) (HPV16 E1/E4), CF405S conjugate, 0.1mg/mL
